Johnson PWM - Search Results

1

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.

Fisher JG, Doyle ADP, Graham LV, Sonar S, Sale B, Henderson I, Del Rio L, Johnson PWM, Landesman Y, Cragg MS, Forconi F, Walker CJ, Khakoo SI, Blunt MD. Fisher JG, et al. Among authors: johnson pwm. Leukemia. 2023 Oct;37(10):2036-2049. doi: 10.1038/s41375-023-01984-z. Epub 2023 Aug 1. Leukemia. 2023. PMID: 37528310 Free PMC article.

2

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.

Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ. Cragg MS, et al. Blood. 2003 Feb 1;101(3):1045-52. doi: 10.1182/blood-2002-06-1761. Epub 2002 Sep 19. Blood. 2003. PMID: 12393541 Free article.

3

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.

Du Y, Honeychurch J, Cragg MS, Bayne M, Glennie MJ, Johnson PW, Illidge TM. Du Y, et al. Blood. 2004 Feb 15;103(4):1485-94. doi: 10.1182/blood-2003-06-2037. Epub 2003 Oct 23. Blood. 2004. PMID: 14576070 Free article.

4

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, Glennie MJ, Cragg MS. Walshe CA, et al. J Biol Chem. 2008 Jun 20;283(25):16971-84. doi: 10.1074/jbc.M708459200. Epub 2008 Apr 21. J Biol Chem. 2008. PMID: 18426802 Free article.

5

Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.

Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, Du Y, Lewington V, Smart J, Thom J, Zivanovic M, Johnson PW. Illidge TM, et al. Blood. 2009 Feb 12;113(7):1412-21. doi: 10.1182/blood-2008-08-175653. Epub 2008 Dec 12. Blood. 2009. PMID: 19074729 Free article. Clinical Trial.

6

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Lim SH, et al. Haematologica. 2010 Jan;95(1):135-43. doi: 10.3324/haematol.2008.001628. Epub 2009 Sep 22. Haematologica. 2010. PMID: 19773256 Free PMC article. Review.

7

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ. Lim SH, et al. Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18. Blood. 2011. PMID: 21768293 Free article.

8

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. White AL, et al. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Cancer Immunol Immunother. 2013. PMID: 23543215 Free PMC article. Review.

9

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.

Williams EL, Dunn SN, James S, Johnson PW, Cragg MS, Glennie MJ, Gray JC. Williams EL, et al. Clin Cancer Res. 2013 Jul 1;19(13):3545-55. doi: 10.1158/1078-0432.CCR-12-3226. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649004 Free PMC article.

10

Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Lee CS, Cragg M, Glennie M, Johnson P. Lee CS, et al. Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164. Br J Clin Pharmacol. 2013. PMID: 23701301 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page